1
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      CTCs in metastatic breast cancer.

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Circulating tumor cells (CTCs), enumerated by the Food and Drugs Administration-cleared CellSearch(®) system, are an independent prognostic factor of progression-free survival (PFS) and overall survival (OS) in metastatic breast cancer (MBC) patients. Several published papers demonstrated the poor prognosis for MBC patients who presented basal CTC count ≥5 in 7.5 mL of blood. Therefore, the enumeration of CTCs during treatment for MBC provides a tool with the ability to predict progression of disease earlier than standard timing of anatomical assessment using conventional radiological tests. Randomized clinical trials are ongoing to demonstrate whether CTCs detected by CellSearch(®) may help to guide treatments in MBC patients and improve prognosis. Moreover, the ability to perform molecular characterization of CTCs might identify a new druggable target in MBC patients. For example, the RT-PCR-based approach AdnaTest BreastCancerSelect(™) showed a high discordance rate in receptor expression between the primary tumors and CTCs. Theoretically, the phenotypic analysis of CTCs can represent a "liquid" biopsy of breast tumor that is able to identify a new potential target against the metastatic disease.

          Related collections

          Author and article information

          Journal
          Recent Results Cancer Res.
          Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer
          Springer Nature America, Inc
          0080-0015
          0080-0015
          2012
          : 195
          Affiliations
          [1 ] Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. agiordano@mdanderson.org
          Article
          10.1007/978-3-642-28160-0_18
          22527507
          636e5a24-d6c5-404f-84c5-f13ba7d002c6
          History

          Comments

          Comment on this article